MEMBERS


Dr. Suzanne Turner

University of Cambridge

Institute Link

Research Topic Paediatric lymphoma and neuroblastoma
Research Interest Suzanne D. Turner, PhD is a Senior Lecturer in tumour biology and pathology at the University of Cambridge. She directs a research group investigating mechanisms of ALK-induced malignancies and has contributed significantly to our understanding of the carcinogenic process having created one of the first murine models of ALK-induced tumour formation. In particular, mechanisms relating to the role of the T cell receptor in ALK-induced lymphomagenesis are an interest of the Turner group.
Publications Publication Link
Contact Division of Molecular Histopathology

Lab Block Level 3, Box 231

Addenbrooke’s Hospital

Cambridge, CB2 0QQ, UK

Telephone: +44 (0)1223 762655

E-Mail: sdt36@cam.ac.uk

Dr. Olaf Merkel

Medical University Vienna

Institute Link

Research Topic Molecular profiling and apoptosis regulation in lymphoma
Research Interest Olaf Merkel is a lecturer in cancer therapeutics and an experienced biochemist. His main research interests are B and T-cell lymphomas. The focus of his group are non-coding RNAs, in particular miRNA and their impact on oncogenesis and cell survival. In particular, he is interested in the role of the oncogenic miR-155 and miR-17-92 clusters. Moreover, recently he became interested in cytokine regulation by BATF and cJUN in T-cell lymphomas. Also how cytokine signals are then transduced to the nucleus by the JAK/STAT pathway. Kinases in this pathway are potential therapeutic targets.
Publications Publication Link
Contact Clinical Institute for Pathology

Medical University of Vienna

Währinger Gürtel,18-20, A-1090 Vienna, Austria

Phone: +43 1 4040036610

E-Mail: olaf.merkel@meduniwien.ac.at


Dr. Gerda Egger

Medical University of Vienna

Institute Link

Research Topic Epigenetics of ALK dependent cancers
Research Interest Gerda Egger is lecturer on epigenetics and tumour biology since 2009. She directs a research group studying the impact of epigenetics in different diseases including cancer. Using mouse models we are trying to understand how epigenetic aberrations are generated and how they can be reversed and remodelled. We are using genome-scale analyses to define targets of differential DNA methylation in patient samples to define epigenetic biomarkers and to discover epigenetic drivers of different pathologies.
Publications Publication Link
Contact Clinical Institute of Pathology

Währinger Gürtel 18-20

1090 Vienna, Austria

Phone: +43 1 40400 63890

E-Mail: gerda.egger@meduniwien.ac.at

Prof. Lukas Kenner

Ludwig Boltzmann Institute for Cancer Research

Institute Link

Research Topic AP-1 in Lymphoma formation
Research Interest

Lukas Kenner is board certified pathologist and an internationally acknowledged expert in comparative pathology. His research interest is the exploration of molecular mechanisms in neoplastic disease, their functional relevance for tumor progression and potential for clinical i8mprovements through diagnostic and prognostic measures. He has generated several transgenic mouse models for investigating the roles of AP-1 and PDGFRB in NPM-ALK transgenic mice.

Publications Publication Link
Contact Ludwig Boltzmann Institute for Cancer Research (LBI-CR)

Währingerstrasse 13A

phone: +43 1 427764111

E-Mail: Lukas.kenner@lbicr.lbg.ac.at


Prof. Šárka Pospíšilová,
Prof. Andrea Janíková

Masaryk University

Institute Link

Research Topic Genomics of lymphoproliferative disorders; role of p53 abnormalities in cancer
Research Interest Prof. S. Pospisilova is head of the research center of Molecular Medicine in CEITEC, MU and also works in the department of Internal Medicine – Hematology and Oncology in the University Hospital Brno. She coordinates national and international research projects in leukaemia and lymphoma and is a member of the board of the European Research Initiative on CLL (ERIC) within the European Leukaemia Net. Her research group studies the genomic background of ALK-related malignancies (with application of NGS and array technologies) and the role of the p53 pathway and microRNAs in these tumours.

Characterization of ALK role in paediatric tumours specifically in neuroblastoma and rhabdomyosarcoma. Introduction of high-throughput analyses of human genomes for diagnostic tests.Study of neuroblastoma and other paediatric CNV (copy number variation) malignancies as epigenetic diseases with aim to better understand role of epigenome in ALK-induced malignancies in general. Identification of potential therapeutic targets in relapsed or refractory paediatric malignancies applicable in clinical practice.

Publications Publication Link (SP)

Publication Link (AJ)

Contact CEITEC

Kamenice 753/5

Brno – Bohunice 625 00, Czech Republic

Phone: +420532234622

E-Mail: sarka.pospisilova@ceitec.muni.cz
E-Mail: ajanikova@fnbrno.cz

Prof. Falko Fend,
Prof. Leticia Qunitanila-Fend

University of Tübingen

Institute Link

Research Topic Molecular Hematopathology
Research Interest Prof. Falko Fend is head of the Department of Pathology and has a long track record in lymphoma research, molecular pathology and as a diagnostic hematopathologist. Prof. Quintanilla-Martinez de Fend, senior staff member and group leader, is a renowned hematopathologist with a long track record in lymphoma research and is an active leading member of international societies and groups in the field. Our research interests include the pathobiology of ALCL, genetics of early stages of lymphoma and the advancement of molecular diagnostics in hematopathology.
Publications Publication Link (FF)

Publication Link (LQF)

Contact Institute of Pathology and Neuropathology

University Hospital Tuebingen

Eberhard-Karls-University

Liebermeisterstrasse 8

72076 Tuebingen, Germany

Phone: 0049/7071-29-82266

E-Mail: falko.fend@med.uni-tuebingen.de
E-Mail: leticia.quintanilla-fend@med.uni-tuebingen.de


Prof. Carlo Gambacorti Passerini

Università degli Studi Milano-Bicocca

Institute Link

Research Topic Clinical research into disease mechanisms of neoplastic disease
Research Interest

Prof. Carlo Gambacorti-Passerini is a leading physician in the field of oncogenic fusion proteins and tyrosine kinase inhibitors. He has contributed significantly to the development of imatinib for the treatment of CML and successfully pioneered an ALK+ lymphoma patient therapy with ALK inhibitors. His research centers on identifying the molecular pathogenesis of hematological cancers using genome sequencing. He is interested in molecular mechanisms governing the transition from chronic phase to blast crisis in CML. In addition he is engaged in target validation of oncogenic fusion genes, structural characterization and screening of small-molecule inhibitors and new tyrosine kinase inhibitors to overcome therapy resistance in patients with ALK+ lymphomas.

Publications Publication Link
Contact Via Pergolesi 33

20900 Monza, Italy

Phone: 0039 0392339553

E-Mail: carlo.gambacorti@unimib.it

Dr. Sylvie Giuriato

The Cancer Research Centre of Toulouse (CRCT)

Institute Link

Research Topic RNA biology in hematological cancers
Research Interest Dr Sylvie Giuriato has focused recently on the role of autophagy following crizotinib therapy in ALK-positive ALCL. The goal is to pursue understanding the role and the regulation (in particular post-transcriptional regulation through microRNAs and/or RNA-Binding proteins) of this process in different ALK-positive tumours, both in basal conditions and following targeted-, chemo- and immuno-therapies.
Publications Publication Link
Contact UMR1037 INSERM-UPS-ERL5294 CNRS

Team 7: RNA biology in hematological cancers

Oncopole de Toulouse, Entrée C,

2 avenue Hubert Curien

CS53717

31037 TOULOUSE Cedex 1 – FRANCE

phone: 0033-5-82-74-15-75

E-Mail: sylvie.giuriato@inserm.fr


Dr. Stephan Mathas

Charité – University Medicine Berlin

Institute Link

Research Topic Mechanisms of transformation in lymphoma
Research Interest Stephan Mathas works as an MD treating in particular patients suffering from malignant lymphomas and group leader at the Max-Delbrück-Centre for Molecular Medicine. His research focuses on the pathogenesis of classical Hodgkin lymphoma and ALCL, for which his laboratory has already identified key molecular defects.
Publications Publication Link
Contact Institute for Hematology, Oncology and Tumorimmunology

Charité University Medical School

Campus Virchow-Klinikum

13353 Berlin, Germany

Phone: 0049 30 94 06 – 28 63

E-Mail: stephan.mathas@charite.de

Dr. Roberto Chiarle

University of Torino

Institute Link

Research Topic In vivo models of ALK-driven tumors and ALK-targeted immunotherapy
Research Interest

Roberto Chiarle has wide expertise in cellular biology, immunology, and molecular biology. He holds clinical qualifications for haematopathology and is currently the recipient of a double appointment as Full Professor and clinical physician at the University of Torino and as Associate Professor at Harvard Medical School. RC is a pioneer in the field of ALK-related lymphoma having generated one of the first mouse models of ALK-induced ALCL. His research aims at therapeutic targeting of ALK by means of specific inhibitors, drugs and immunotherapy. His objectives are therefore to improve our understanding of the molecular mechanisms of

  • ALK-driven transformation with in vitro and in vivo models
  • Mechanisms of chromosomal translocation formation in different tissues
  • Cancer Immunotherapy of ALK-driven cancers

Publications Publication Link
Contact Department of Molecular Biotechnology and Health Sciences

University of Torino

Via Santena, 7 – 10126 Torino, ITALY

Phone: +39 011.633.6861

E-Mail: roberto.chiarle@unito.it


Prof. Wilhelm Woessmann,
Dr. Christine Damm-Welk

Justus-Liebig-University Giessen, NHL-BFM study centre

Institute Link

dammwelk

Research Topic Molecular diagnosis of childhood ALCL; Immune response to ALK in ALCL
Research Interest Wilhelm Woessmann is a paediatric oncologist, co-chair of the NHL-BFM study group and an active member of the European paediatric NHL study group (EICNHL). His translational research includes biological risk factors, molecular biology and immune response against ALK in children with ALCL.
Publications Publication Link
Contact

Dept of Pediatric Hematology and Oncology

Justus-Liebig-University

Feulgenstr. 12

35392 Giessen

Phone: +49- (0) 641-985-43462 or -43400

E-Mail: wilhelm.woessmann@paediat.med.uni-giessen.de
E-Mail: Christine.Damm-Welk@paediat.med.uni-giessen.de

Dr. Laurence Brugieres,
Dr. Veronique Minard

Institute Gustave-Roussy

Institute Link

Research Topic Immunology of ALCL
Research Interest Laurence Brugieres, MD is a paediatric oncologist involved in ALCL trials since 1999. She is engaged in a research programme devoted to biological mechanisms involved in immunogenicity of ALCL in children and investigates immune responses against ALK according to the type of treatment given to the patients.
Publications Publication Link
Contact Maison du projet

39, rue Camille Desmoulins

94 800 Villejuif

Phone: + 33 (0)1 42 11 50 05

E-Mail: Laurence.brugieres@gustaveroussy.fr
E-Mail: Veronique.MINARD@gustaveroussy.fr


Prof. Bengt Hallberg,
Prof. Ruth Palmer

University of Gothenburg

Institute Link (BH)

Institute Link (RP)

Research Topic Mechanisms behind the oncogene ALK in cell and mouse model systems
Research Interest Bengt Hallberg has been working with receptor tyrosine kinase-mediated signalling since the beginning of the 1990’s. Recently his research has been addressing the role of ALK in the pathogenesis of neuroblastoma and has shown a dependence on ALK for MYCN transcription. He is investigating the function and importance of ALK RTK’s and differences in constitutively active ALK RTK mediated signalling at the molecular level as compared with wild type ALK in relevant cell models. This work is also carried out in mouse models which we have developed in with the aim of addressing ALK signalling in vivo.

Ruth Palmer has been working with ALK in the fruitfly Drosophila melanogaster since 1996. The laboratory is investigating ALK signal transduction with an interest in its role in developmental processes employing Drosophila melanogaster and mouse model systems. Our aim is to understand the importance and function of the ALK receptor tyrosine kinase during both normal and pathological developmental process.

Publications Publication Link (BH)

Publication Link (RP)

Contact Medicinaregatan 9 a

413 90, Göteborg

Phone: +46 31 7863815

E-Mail: bengt.hallberg@gu.se
E-Mail: ruth.palmer@gu.se

Prof. Justus Duyster,
Dr. Lena Illert

University Hospital Freiburg

Institute Link

illert

Research Topic Identification and Eradication of ALCL-Lymphoma Stem cells
Research Interest Prof. Justus Duyster is head of Medical Clinic for Hematology, Oncology and stem cell transplantation and has a long track record in the field of lymphoma and leukemia research and oncogenic fusion proteins. The Duyster group has previously established a murine bone marrow transplantation model and showed that retroviral NPM-ALK transduction into murine bone marrow leads to a histocytic or plasmocytic disease depending on viral titre. To induce a T-lymhoid ALCL in mice, we currently expressed NPM-ALK in a spatio-temporal manner. We will use this model to study lymphoma stem cells in NPM-ALK driven lymphomas and the eradication of the Lymphoma initiating population. Moreover, our current research involves the signal-transduction and the crosstalk between the DNA-damage stress axis in lymphoma initiation and progression.
Publications Publication Link (JD)

Publication Link (LI)

Contact Prof. Dr. Justus Duyster/ Dr. Lena Illert

University Medical Center Freiburg

Dept. of Hematology, Oncology and Stem Cell Transplantation

Hugstetter Str. 55

79106 Freiburg, Germany

Tel: 0761-270-34060

Fax: 0761-270-32060

E-Mail: Justus.Duyster@uniklinik-freiburg.de
E-Mail: lena.illert@uniklinik-freiburg.de

 

ns-logo

NAKED SCIENCE LTD

The Naked Scientists are a multi-award-winning initiative comprising a group of Cambridge University-based scientists and doctors who are also specialists in science communication techniques including radio broadcasts, podcasts, published books and online media. The team are supported by UK research councils and air science material live on radio networks internationally each week including across the UK (BBC 5 Live), Australia (ABC Radio National), South Africa (Primedia) and Europe (Talk Radio Europe). Their podcasts have been downloaded 30 million times in the last 4 years.

www.thenakedscientists.com

tisgno_logo

TISSUEGNOSTICS GMBH

TissueGnostics was founded in April 2003 and has a proven track record in developing innovative and trend-setting products in the field of tissue cytometry. While flow cytometry is restricted to cells in suspension (e.g. blood) the tissue cytometers made by TG – termed “HistoFAXS” and “TissueFAXS” work with fixed material.

www.tissuegnostics.com

ROCHE AUSTRIA GMBH

Roche Austria GmbH is one of Austria’s leading suppliers of pharmaceuticals. In 2013 the company employed approximately 650 people in Austria (Vienna and Graz). Roche leads the overall Austrian pharmaceutical market and is number one in the hospital market and in cancer drugs.

www.roche.at

GALKEM SRL

GALKEM SRL., created in 2013, is a University spinoff company devoted to finding new small molecule inhibitors of the ALK tyrosine kinase for the therapeutic targeting of crizotinib-resistant disease. In addition, GALKEM SRL. provides a Next Generation Sequencing service for academic partners. It offers a stimulating environment where industrial research is embedded in academic laboratories working at the interface of chemistry and biology.

www.galkem.com

BIOLUTION GMBH

Biolution is an experienced service provider for biotech and university clients alike; they are specialized in supporting consortia in the initiation and execution of EU funding programs. Biolution combines management experience and scientific expertise, providing the necessary skills to meet the challenges of EU projects. Over the past decade, Biolution has managed 9 projects within the FP6 and FP7 frameworks worth around €20 million.

Since its foundation in 2002, Biolution has become Austria´s premier service provider for the application, implementation, and management of research projects in the life sciences. They take pride in their high success rate and are proactively adapting services to the challenges of Horizon 2020.

In addition, Biolution regularly contributes to national science events and organises science communication activities for customers.

www.biolution.net

VARIONOSTIC GMBH

Varionostic is a spin-off company of the University (Hospital) of Ulm/Germany (founded 2006). Varionostic is Europe’s leading expert for DNA methylation analysis using the most up-to-date platforms of Pyrosequencing and MassARRAY. Varionostic offers outstanding tailored services ranging from assay design to data analysis to customers from industry and academia. Scientists can also profit from predesigned methylation assays developed within their own research facilities. Besides epigenetics, Varionostic also run genotyping and other DNA analytical projects.

www.varionostic.de

CENTRAL EUROPEAN SOCIETY OF ANTI-CANCER RESEARCH (CESAR)

The CESAR Central European Society for Anticancer Drug Research – EWIV is a European Non-Profit Organization aiming to foster research and development of novel anti-tumour agents, therapies and therapeutic strategies in oncology. CESAR comprises scientists from basic research, preclinical and clinical Oncology in Austria, Germany and Switzerland. Since 2005, the CESAR Central Office (CCO) has functioned as a “hub” for all clinical trials where CESAR is either participating via its network of clinical centres or in its capacity as Sponsor (Investigator-Initiated Trials – IITs). Quality and adherence to standards according to ICH-GCP are a top priority for CESAR.

www.cesar.or.at

biobank

BIOBANK GRAZ

Biobank Graz is the largest academic biobank in Europe and is a member of the newly formed European biobanking network BBRMI-ERIC and the Austrian network BBMRI.AT. Biobank Graz offers its services not only to scientists at the Medical University of Graz, but also to scientists from academia and industry worldwide. Due to its leading position in automation of collection and storage of samples, the maintenance of highest sample quality is one of its key features.

www.medunigraz.at/strategische-projekte/biobank

CAMBRIDGE LIFE SCIENCES

Cambridge Life Sciences are an in vitro diagnostic company specialising in autoimmune diseases; they develop, manufacture and distribute diagnostic test kits and reagents worldwide.
(ISO 13485:2003 and ISO 9001:2000 certified)

www.clsdiagnostics.com

SOFIGEN

Sofigen was established as a spin-off company from Masaryk University (MU) focused on the development of molecular biological diagnostic approaches mainly for haematological and oncological diseases. One of their objectives is the application of high throughput genomics approaches to diagnostics and personalized medicine. The company was established in January 2013 and during its short history has successfully integrated into several collaborative research projects.

www.sofigen.cz/en